Background: There is limited data on dolutegravir (DTG)-associated weight gain from settings with a dual burden of HIV and overnutrition.
Methods: In Eswatini (at Matsanjeni), among 156 and 160 adult patients on DTG-based and EFV-based antiretroviral therapy (ART), respectively, we studied excessive weight gain (BMI at 24 months ART greater than baseline and ≥25 kg/m).
Results: The median BMI increase in DTG-based patients was 1.